Combination pharmacotherapy for achievement and maintenance of vascular patency

Stroke

Volumn 40, Issue 3 SUPPL. 1, 2009, Pages

  Pancioli, Arthur M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Pharmacotherapy; Reperfusion; Vascular patency

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; BLEEDING; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROCIRCULATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANKIN SCALE; REPERFUSION; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME;

DRUG THERAPY; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL THROMBOSIS; STROKE; VASCULAR PATENCY;

EID: 62949084142     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.529800     Document Type: Conference Paper

References (24)

1. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59: 862-867.
2. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 1990;67:1552-1561.
3. Kawai H, Umemura K, Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. J Pharmacol. 1995;69:143-148.
4. Morris DC, Zhang L, Zhang ZG, Lu M, Berens ICL, Brown PM, Chopp M. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635-2640.
5. Tamao Y, Kikumoto R. Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. Semin Thromb Hemostasis. 1997;23:523-530.
6. Tanaka Y, Kawabata S, Sin R. Therapeutic effect of argatroban (MD-805) antithrombotic agent in the acute stage of cerebral thrombosis. J Clin Ther Med. 1987;3:133-142.
7. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. J Am Coll Cordial. 1999;33: 1879-1885.
8. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Bursting MJ, Brown PM. Argatroban anticoagulation in patients with acute ischemie stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682.
9. Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikuluk R, Garami Z, Shaw SG, Matherne DE, Moye LA, Alexandrov AV, Grotta JC. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63:1057-1062.
10. Mikulik R, Dufek M, Goldemund D, Reif M. A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke. Eur J Neurol. 2006;13:1106-1111.
11. Proimos G. Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombol. 2001;11:99-110.
12. Gold HK, Yasuda T, Jang IK, Guerrero JL, Fallen JT, Leinbach RC, Collen D. Animal models for arterial thrombolysis and prevention of reocclusion: erythrocyte-rich versus platelet-rich thrombus. Circulation. 1991;83(suppl IV):IV-26-IV-40.
13. Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant plate-let-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990;16:172g-1735.
14. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D. A canine model of coronary artery thrombosis with super-imposed high grade stenosis for the investigation of rethrombosis after thrombolysis. J Am Coll Cardiol. 1989;13:1409-1414.
15. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999;99:2720-2732.
16. Morris DC, Silver B, Mitsias P, Lewandowski C, Patel S, Daley S, Zhang ZG, Lu M. Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. Acad Emerg Med. 2003;10:1396-1399.
17. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke. 2004;35: 705-709.
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488-1497.
19. Abou-Chebl A, Bajzer CT, Krieger DW, Furlan AJ, Yadav JS. Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. Stroke. 2005;36:2286-2288.
20. Deshmukh VR, Fiorella DJ, Albuquerque FC, Frey J, Plaster M, Wallace RC, Spetzler RF, McDougall CG. Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy. Neurosurgery. 2005;56:46-54; discussion 55.
21. Gupta R, Vora NA, Horowitz MB, Tayal AH, Hammer MD, Uchino K, Levy EI, Wechsler LR, Jovin TG. Multimodal reperfusion therapy for acute ischemic stroke: factors predicting vessel recanalization. Stroke. 2006;37:986-990.
22. Qureshi AI, Harris-Lane P, Kirmani JF, Janjua N, Divani AA, Mohammad YM, Suarez JI, Montgomery MI. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an openlabel, dose-ranging, phase I study. Neurosurgery. 2006;59:789-796, discussion 796-797.
23. Seitz RJ, Hamzavi M, Junghans U, Ringleb PA, Schranz C, Siebler M. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke. 2003;34:1932-1935.
24. Pancioli A, Brott T, Tomsick T, Khoury J, Bean J, Del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J, Kasner SE, Kidwell CS, Kwiatkowski T, Libman R, Mackenzie R, Scott PA, Starkman S, Thurman J; for the CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke (the CLEAR Stroke Trial). Stroke. 2008;39:3268-3276.